Physician profile
Hazel Aguda
NPI 1871136192
$9,468.23
in general payments reported to CMS, 2019-2025
26 companies · $1,681 in 2025
The $1,681 reported for 2025 was more than what 99% of Gastroenterology (Registered Nurse) providers received nationally (typical 2025 total: $239).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,936 · 2022: $1,905 · 2023: $2,077 · 2024: $1,869 · 2025: $1,681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,350 · Travel and Lodging: $263 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,350.32 |
| Travel and Lodging | $263.35 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,980.33 | 2021-2025 | Rinvoq, Linzess, Mavyret |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $951.15 | 2021-2025 | Xifaxan, Trulance |
| Axonics, INC. | $620.35 | 2022-2023 | Axonics |
| Madrigal Pharmaceuticals | $616.54 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $549.52 | 2021-2025 | Entyvio, Gattex, Eohilia |
| E.R. Squibb & Sons, L.L.C. | $407.96 | 2021-2024 | Zeposia |
| Celgene Corporation | $383.57 | 2021-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $326.54 | 2021-2023 | |
| Gilead Sciences, INC. | $299.35 | 2021-2024 | |
| Pfizer INC. | $253.70 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $172.23 | 2021-2024 | Dificid |
| Genzyme Corporation | $121.52 | 2024 | |
| Inspire Medical Systems, INC. | $118.62 | 2023 | Inspire |
| Braintree Laboratories, INC. | $103.11 | 2021-2025 | Suflave, Sutab |
| Mylan Specialty L.P. | $93.53 | 2023 | Yupelri |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $89.10 | 2024-2025 | Voquezna |
| Redhill Biopharma INC. | $85.27 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $77.51 | 2024-2025 | Zenpep |
| Ipsen Biopharmaceuticals, INC | $54.42 | 2024-2025 | Iqirvo |
| Janssen Biotech, INC. | $33.12 | 2022 | |
| Intercept Pharmaceuticals, INC. | $31.52 | 2021 | |
| Lilly USA, LLC | $27.88 | 2024 | Omvoh |
| Novo Nordisk INC | $20.80 | 2025 | Wegovy |
| Vivus LLC | $20.60 | 2023 | Pancreaze |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.83 | 2022 | |
| Intra-Sana Laboratories | $10.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hazel Aguda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.